Related Experiment Videos
Reduced-intensity allogeneic transplantation for lymphoma
Karen E Kogel1, Peter A McSweeney
1University of Colorado Health Sciences Center, Denver 80262, USA.
Current Opinion in Oncology
|August 23, 2002
Summary
Reduced-intensity allogeneic transplants show promise for treating hematologic malignancies like lymphoma, with over 66% of patients achieving responses. Further research is needed to optimize this graft-versus-tumor therapy and manage risks like graft-versus-host disease.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Reduced-intensity allogeneic transplants are an emerging treatment for hematologic malignancies.
- These transplants leverage graft-versus-tumor effects to combat cancer.
- Lymphomas are a significant target for these innovative therapies.
Purpose of the Study:
- To review published data on reduced-intensity allogeneic transplants in lymphoma patients.
- To assess the safety and efficacy of this treatment approach.
- To identify areas for future research and clinical trials.
Main Methods:
- Systematic review of approximately 40 published reports.
- Analysis of outcomes in 368 lymphoma patients undergoing reduced-intensity allogeneic transplants.
- Evaluation of response rates, remission durations, and adverse events.
Main Results:
- Reduced-intensity allogeneic transplants were generally well-tolerated.
- An overall response rate of 66.3% was observed, with most responses being complete.
- Encouraging results were seen in heavily pretreated and older patients, including those with refractory or relapsed lymphomas.
Conclusions:
- Reduced-intensity allogeneic transplants offer a viable treatment option for lymphomas, demonstrating significant efficacy.
- Graft-versus-tumor effects may be sufficient for curing some lymphomas.
- Further research, including controlled trials in earlier-stage disease, is warranted to refine the treatment and mitigate risks such as graft-versus-host disease.